
ACADIA Pharma (ACAD) Stock Forecast & Price Target
ACADIA Pharma (ACAD) Analyst Ratings
Bulls say
ACADIA Pharmaceuticals Inc demonstrates a positive outlook driven by a robust growth trajectory, highlighted by a fiscal year 2024 total sales increase of 32% year-over-year, underscoring effective strategies to enhance brand awareness for NUPLAZID and DAYBUE, which are critical to its revenue generation. The company's solid market position is further reinforced by strong commercial metrics for DAYBUE, including improved patient adherence and an expanding diagnosed population, with fourth-quarter revenue of $97 million exceeding expectations. Additionally, ACADIA's financial stability is strengthened by a significant cash position of $756 million, enabling the company to support its commercial operations and advance its product pipeline in the neurology sector.
Bears say
ACADIA Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock. Key issues include anticipated declines in net pricing for DAYBUE due to Medicare Part D redesign, coupled with negative sentiment surrounding NUPLAZID leading to reduced patient starts and sales growth. Additionally, commercial risks are highlighted, particularly concerning NUPLAZID's market performance, potentially slower uptake of DAYBUE, and uncertainties regarding the performance of other pipeline candidates, which could hinder revenue growth and overall business performance.
This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.
ACADIA Pharma (ACAD) Analyst Forecast & Price Prediction
Start investing in ACADIA Pharma (ACAD)
Order type
Buy in
Order amount
Est. shares
0 shares